Trials / Unknown
UnknownNCT04761653
Study of the Inflammatory Microenvironment in Atypical Meningiomas
Prognostic Impact of the Inflammatory Microenvironment in Atypical Meningiomas
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 84 (estimated)
- Sponsor
- Central Hospital, Nancy, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Atypical meningiomas represent 15% of meningiomas. They present a high rate of recurrence, and therapeutic strategies are limited. There is a need for novel treatment strategies, such as immuotherapy. This is a retrospective study including 84 patients with primary diagnosis of atypical meningiomas. The presence of T cells (CD4, CD8, Treg and memory T cells) and mature dendritic cells will be quantified on whole tissue sections stained by immunohistochemistry (CD4, CD8, FOXP3, CD45RO and CD208). This could allow us to identify novel biomarkers for survival, and facilitate the selection of patients who may benefit from immunotherapeutic modalities.
Conditions
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2021-06-30
- Completion
- 2021-06-30
- First posted
- 2021-02-21
- Last updated
- 2021-02-21
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04761653. Inclusion in this directory is not an endorsement.